We could not find any results for:
Make sure your spelling is correct or try broadening your search.
VANCOUVER, British Columbia, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc.Β (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the βCompanyβ or βAlgernonβ) a clinical stage...
VANCOUVER, British Columbia, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc.Β (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the βCompanyβ or βAlgernonβ) a clinical stage...
VANCOUVER, British Columbia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc.Β (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the βCompanyβ or βAlgernonβ) a clinical stage...
VANCOUVER, British Columbia, July 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc.Β (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) (the βCompanyβ or βAlgernonβ), a clinical stage...
VANCOUVER, British Columbia, July 06, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc.Β (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the βCompanyβ or βAlgernonβ) a clinical stage...
VANCOUVER, British Columbia, June 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc.Β (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the βCompanyβ or βAlgernonβ) is pleased to announce that...
VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc.Β (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the βCompanyβ or βAlgernonβ) announces it has initiated a...
VANCOUVER, British Columbia, May 27, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc.Β (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the βCompanyβ or βAlgernonβ) is pleased to highlight an...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions